Kaleido Biosciences, Inc.

Equities

KLDO

US4833471000

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:10:26 2024-04-22 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	+9,900.00%

2022	Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P Global BMI Index	CI
2022	Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P TMI Index	CI

Kaleido Biosciences, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021

May 04, 2021 at 05:30 am EDT

Kaleido Biosciences, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2021. For the quarter, the company's loss from operations was $22,348,000 compared to $19,054,000 a year ago. Net loss was $23,042,000 compared to $19,551,000 a year ago. Net loss per share - basic and diluted was $0.58 compared to $0.64 a year ago.

Latest news about Kaleido Biosciences, Inc.

Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P Global BMI Index	22-04-20	CI
Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P TMI Index	22-04-20	CI
Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from NASDAQ Composite Index	22-04-15	CI
Top Premarket Gainers	22-04-14	MT
Top Premarket Gainers	22-04-13	MT
Top Midday Decliners	22-04-08	MT
Kaleido Biosciences Ceases Operations, Will Delist From Nasdaq; Shares Fall	22-04-08	MT
Kaleido Biosciences, Inc. Announces Cessation of All of the Company’s Ongoing Operations	22-04-08	CI
Kaleido Biosciences, Inc. Announces Management Changes	22-04-08	CI
Chardan Cuts Kaleido Biosciences to Neutral From Buy, PT to $1.70 From $3 After Securities Filing Discloses Strategic Review, Potential Liquidation, 'Extremely Limited' Active Development Initiatives in Pipeline	22-04-04	MT
Kaleido Biosciences Initiated Process to Explore Strategic Alternatives	22-04-04	CI
Kaleido Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-01	CI
Kaleido Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	22-03-31	CI
Kaleido Biosciences, Inc. Announces Board Resignations	22-03-17	CI
Radius Health Names New CFO	22-03-16	MT
North American Morning Briefing : Stock Futures -3-	22-03-16	DJ
History shows stocks can weather rate hike cycle	22-03-16	RE
Epizyme Doses First Patient In Phase 3 Study On Potential Lymphoma Treatment, Names New COO	22-03-15	MT
Kaleido Biosciences, Inc. Announces Resignation of Jerald Korn, the General Counsel and Chief Operating Officer, Effective March 18, 2022	22-03-09	CI
North American Morning Briefing : Stock Futures -3-	22-03-02	DJ
Chardan Adjusts Kaleido Biosciences' Price Target to $3 from $11, Keeps Buy Rating	22-01-31	MT
Piper Sandler Adjusts Kaleido Biosciences' Price Target to $4 From $19, Reiterates Overweight Rating	22-01-31	MT
Kaleido Biosciences Halts Phase 2 Study on Chronic Obstructive Pulmonary Disease	22-01-31	MT
Kaleido Biosciences, Inc. Decides Halt Work on a Planned Phase 2 Chronic Obstructive Pulmonary Disease Study	22-01-28	CI
Kaleido Reports Findings From Study Data of Proposed Inflammatory Bowel Disease Treatment	22-01-21	MT

Chart Kaleido Biosciences, Inc.

Duration

Period

More charts

Company Profile

Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on microbiome organs to treat disease and improve human health. The Companyâs product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of existing microbes. It is advancing a pipeline of MMT candidates to address a range of diseases and conditions with unmet patient needs. KB109 and KB174 are the MMT candidates for development for the prevention of infections caused by multi-drug resistant (MDR) bacteria. The nomination of these candidates resulted from their performance relative to a range of other MMTs in ex vivo screening of microbiome samples from healthy volunteers as well as microbiome samples from intensive care unit patients in an experimental set-up that specifically focused on determining the potential of MMTs to decrease the relative abundance of a panel of pathogenic bacteria.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KALEIDO BIOSCIENCES, INC.	+9,900.00%	4.26K
IQVIA HOLDINGS INC.	-0.02%	42.11B
LONZA GROUP AG	+43.29%	40.08B
MODERNA, INC.	+5.04%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+5.25%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.83%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.94B
MEDPACE HOLDINGS, INC.	+22.75%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.44%	11.01B

Other Biotechnology & Medical Research